Abstract: A composition is provided comprising as component (A) at least one insecticide; and as component (B) at least one fertilizer. The composition is effective in controlling nematodes and in promoting plant growth. The at least one insecticide is preferably selected from thiodicarb, abamectin, imidacloprid, fipronil and mixtures thereof. The fertilizer component preferably comprises one or more amino acids and one or more micronutrients. A method of controlling nematodes and/or promoting plant growth using a combination of component (A) and component (B) is also provided.

Abstract: The invention relates to a process for treating keratin fibres, which comprises the application of a composition comprising: (a) one or more alkoxysilanes comprising solubilizing function(s) of formula R1Si(OR2)z(R3)x(OH)y, and/or hydrolysis products thereof and/or oligomers thereof, (b) one or more alkylalkoxysilanes of formula (R4)mSi(OR5)n and/or hydrolysis products thereof and/or oligomers thereof, and (c) water in an amount of greater than 30% by weight relative to the total weight of the composition. The invention also relates to a composition comprising components (a), (b) and (c), and (d) one or more thickeners.

Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

Abstract: An antimicrobial personal cleansing composition comprises: (i) an aqueous continuous phase including cleansing surfactant, (ii) a dispersed phase including dispersed particles of zinc-containing antimicrobial agents; and (iii) a solubilised oily liquid conditioning agent for skin and/or hair; which is light mineral oil having a kinematic viscosity of 3 to 5 cS (mm2·s?1) at 40° C. and is solubilised in wormlike micelles in the aqueous continuous phase via the incorporation of an inorganic electrolyte and a linker molecule of formula R(X)n, wherein R is a C6-C10 aryl ring or a C3-C14 mono-, di- or trivalent alkyl or hydroxyalkyl chain; n is 1 to 3 and each X is independently selected from —OH, —COOH and —COO?M+ groups, where M is an alkali metal, ammonium or alkanolammonium cation; and in which the level of solubilised oily liquid conditioning agent is 0.45 to 3% by weight based on the total weight of the composition.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: Some embodiments are directed to a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, to be used as a drug for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer in association with a eukaryotic cell for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to the use of a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, for manufacturing a drug for the treatment of tissue lesions. Some other embodiments can be used in particular in the veterinary and pharmaceutical fields.

Abstract: An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.

Abstract: The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp. or coccidia sp based diseases or other enteric diseases or by generally improving gastro intestinal health or function.

Abstract: The present invention relates to compositions and methods to provide continuous and controlled release of therapeutic agent(s) during a procedure such as an interventional vascular procedure, e.g., to reduce acute and chronic complications and improve outcomes.

Abstract: Disclosed is an external wound dressing formed of a bioprotein scaffolding that may include a pressure-sensitive adhesive impregnated in the bioprotein scaffolding. A method of wound treatment can include adhering an external wound dressing formed of a bioprotein scaffolding to an external injury site. Another method can include applying an adhesive to the skin of a patient, placing an external wound dressing formed of a bioprotein scaffolding over an injury site on the skin of the patient, and applying a sealing adhesive on top of the bioprotein scaffolding. Yet another method can include applying an adhesive to the skin of a patient, placing an external wound dressing formed of a bioprotein scaffolding over an injury site on the skin of the patient that has not been stitched, and applying a sealing adhesive on top of the bioprotein scaffolding.

Abstract: Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.

Abstract: Provided herein are nanoparticle compositions comprising an organophosphate compound and pharmaceutically acceptable carriers.

Abstract: A cosmetic concentrate base composition and cosmetic compositions for use as creams or lotions utilizing the same, the cosmetic concentrate base composition including approximately 20% to 25% by weight of a first component, the first component being a phospholipid component; approximately 10% to 40% by weight of a second component, the second component being a lipid component; and approximately 4% to 5% by weight of a third component, the third component being a hydrophilic component.

Abstract: The present disclosure provides silicone-based biophotonic compositions and methods useful in phototherapy. In particular, the silicone-based biophotonic compositions of the present disclosure include a silicone phase and a surfactant phase, wherein the surfactant phase comprises at least one chromophore solubilized in a surfactant. The silicone-based biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and scarring, as well as various other skin disorders.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

Abstract: This invention is a hydrogel capsule with a fragrance encapsulated therein during the polymerization process. The hydrogel capsule is of use in fabric care or personal care formulations.

Abstract: A composite dura substitute implant for implantation at a dura defect site having a porous layer that provides an osteoconductive scaffold for bony ingrowth, a porous layer that provides a scaffold for regeneration of collagen at a dura surface, and an intervening layer for preventing cerebrospinal leakage is disclosed. The composite dura substitute implant facilitates regeneration of dura mater and promotes osteointegration with bony tissue. Methods of manufacturing such an implant and methods of treatment using such composite dura substitute implants are further disclosed.